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Organ Procurement and Transplant Network (OPTN)
policy currently requires the testing of all potential
organ donors for human T-cell lymphotrophic virus
(HTLV)-1/2. Most Organ Procurement Organizations
(OPO) use the Abbott HTLV-I/HTLV-II Enzyme Im-
munoassay (EIA). This assay will no longer be man-
ufactured after December 31, 2009; the only commer-
cially available FDA-licensed assay will be the Abbott
PRISM HTLV-I/II assay which poses many challenges to
OPO use for organ donor screening. As a result, screen-
ing donors for HTLV-1/2 in a timely manner pretrans-
plant after December 31, 2009 will be challenging. The
true incidence of HTLV-1 in United States (U.S.) organ
donors is not well described but appears to be low
(∼0.03–0.5%). HTLV-1 is associated with malignancy
and neurological disease; HTLV-2 has not been convinc-
ingly associated with disease in humans. Donors that
are HTLV-1/2 seropositive are infrequently used despite
most results being either false positive or resulting
from HTLV-2 infection. There is urgent need to encour-
age the development of assays, instruments and plat-
forms optimized for organ donors that can be used to
screen for transmissible disease in donors; these must
have appropriate sensitivity and specificity to identify
all infections while minimizing organ loss through false
positive testing.
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Introduction
Human T-cell lymphotrophic Virus 1 (HTLV)-1 is a delta retro-
virus endemic in the Caribbean, parts of South America,
West Africa, Asia and Oceania. In the Caribbean, 2–5% of
adults are infected (1). In the United States (U.S.), 0.035–
0.046% of blood donors are infected with HTLV-1 or HTLV-2
(2). Breast feeding is the most common form of transmis-
sion. Intravenous drug use, sexual intercourse, solid or-
gan transplantation (SOT) and transfusion of cell-containing
blood products (14.4–47.3% of recipients) may also result
in transmission of infection (3,4).
HTLV-1 is associated with development of acute T-cell
leukemia/lymphoma (ATL) in 2–5% of infected individuals
and HTLV-1-associated myelopathy/tropical spastic para-
paresis (HAM/TSP) in a smaller percentage (4). Other in-
flammatory disorders have been associated with HTLV-1
and there is no reliably effective treatment. Most individu-
als have no clinical sequelae of HTLV-1 infection.
HTLV-2 is primarily found in intravenous drug users and sex-
ual contacts of infected persons and is endemic in Ameri-
can Indian populations and in West and Central Africa. Un-
like HTLV-1, the link between HTLV-2 and human disease
is uncertain, although there have been occasional case re-
ports of neurological disease, inflammatory disorders and
leukemia in infected patients (5).
An enzyme-linked immunosorbent assay (EIA) is currently
used to screen organ donors for HTLV-1/2. These tests do
not distinguish between HTLV-1/2. This test is sensitive
but lacks significant specificity and therefore the positive
predictive value is low when applied to low seroprevalence
populations (6,7). A positive EIA result can be confirmed by
a Western blot or specific line immunoassay, although this
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is not standard practice for organ donation. In many cases
these confirmatory assays distinguish between HTLV-1 and
HTLV-2 but none are FDA-licensed or approved for this pur-
pose. Polymerase chain reaction (PCR) tests may also be
useful to confirm infection and can distinguish between
infection with HTLV-1 and HTLV-2. At present, no FDA-
licensed, commercially available nucleic acid test (NAT)
with a turnaround time appropriate for donor screening
is available.
Currently, OPTN policy requires that all potential solid or-
gan donors are tested for HTLV-1/2 using an FDA-licensed
screening test (8). There are presently 3 FDA-licensed tests
for this purpose (9): the Abbott HTLV-I/HTLV-II Enzyme Im-
munoassay (EIA), Abbott PRISM HTLV-I/HTLV-II and the
bioMerieux-Vironostika HTLV-I/II Microelisa System. Most
OPOs currently use the Abbott HTLV-I/HTLV-II EIA test (10)
but this system will no longer be manufactured after De-
cember 31, 2009 and the bioMerieux system is no longer
commercially available. The Abbott PRISM HTLV I-II assay
will be the only commercially available licensed test after
December 31, 2009. It is designed to test large numbers of
samples in a high-throughput setting and is not optimized
to the time constraints associated with organ donation.
Given changing availability of FDA licensed assays for HTLV-
1/2, the OPTN/UNOS Ad Hoc Disease Transmission Ad-
visory Committee (DTAC) requested the formation of an
advisory group (Table 1) to gather information regarding
the need for HTLV-1/2 screening and possible alternative
screening strategies. The purpose of this paper is to report
the findings of this group.
Currently Licensed HTLV-1/2 Screening Tests
Abbott PRISM HTLV-I/II assay
The Abbott PRISM HTLV-I/II assay is a chemiluminescence
immunoassay for HTLV-1/2 screening and is part of an au-
tomated testing system designed for high throughput labs.
In volunteer blood donors, the specificity of the assay was
99.93%. Sensitivity of the assay is estimated to approach
100% (11).
Abbott HTLV-I/II EIA
The Abbott HTLV-I/II EIA is less expensive than the PRISM
system and practical for OPO labs. Specificity of the assay
is estimated at 99.73% among blood donors and sensitivity
is also estimated to approach 100% (12).
bioMerieux–Vironostika HTLV-I/II Microelisa System
The bioMerieux ELISA assay is not commercially available
in the United States. The manufacturer estimates a speci-
ficity of 99.95% for this test; sensitivity was 100% com-
pared to other licensed and confirmatory tests (13).
Table 1: Ad Hoc HTLV Donor Screening Advisory Group
Membership
Member Organization
Daniel Kaul, Chair University of Michigan (TID)




Bradley Eisenbrey Gift of Life (OPO Lab Director)
Mary D. Ellison UNOS
David Hull Organ Availability Committee
Rick Hasz Gift of Life (OPO)/OPTN/UNOS
Operations
Bob Higgins Rush University (Surgery)/OPTN/UNOS
Immediate Past President
Michael Ison Northwestern University
(TID)/OPTN/UNOS DTAC
Andrés Jaramillo Gift of Hope Organ and Tissue Donor
Network (OPO Lab Director)
Lin Johnson McGaw OPTN/UNOS
Marilyn Levi University of Colorado (TID)
Michael Marvin University of Louisville (Surgery)
Mark Mathieson Abbott
Bob Metzger OPTN/UNOS Medical Director
Marek Nowicki NIT Laboratory
Jeff Orlowski Ctr. for Donation & Transplantation
(OPO)/OPTN/UNOS OPO Committee
Carol Pancoska LABs-Inc., Centennial, CO
Timothy L. Pruett University of Virginia (Surgery,
TID)/OPTN/UNOS DTAC
David Snydman Tufts Medical Center (TID)
Sarah Taranto UNOS
Charles Wright LifeLink (OPO)
James Wynn Medical College of
Georgia/OPTN/UNOS President
OPO = Organ Procurement Organization; TID = transplant infec-
tious diseases; OPTN = Organ Procurement and Transplantation
Network; UNOS = United Network for Organ Sharing; DTAC = Ad
Hoc Disease Transmission Advisory Committee.
Representatives of HRSA, FDA and CDC were present as
observers.
Experience with the Use of HTLV-1/2
Positive Organs
Several case reports described likely donor-derived trans-
mission of HTLV-1 after SOT (Table 2); in some of these
reports, recipients developed HTLV-1-associated disease
(14–17). The most definitive case occurred in Spain;
three seronegative recipients of an HTLV-1/2 seropositive
donor developed myelopathy within 2 years of transplan-
tation (16). Less definitive reports include a pretransplant
seronegative renal recipient without other identifiable risk
factors who developed HAM/TSP 4 years after transplan-
tation (14). A documented case of HTLV-1 transmission
without evidence of disease at 4 years follow up in a recip-
ient of a living related renal donor (15), and a seronegative
renal transplant recipient who developed ATL after trans-
plant; the HTLV-1 status of the donor is not described (17).
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Table 3: Number of donors and organs recovered and transplanted for HTLV-1/2 screen-positive donors: United States, 1999–2008
Organ
Year of Donors Heart Kidney Kidney pancreas Liver Lung Pancreas Total
transplant N N N N N N N N
1999 3 0 0 0 2 0 0 2
2000 5 1 0 0 2 1 0 4
2001 3 0 2 0 1 0 0 3
2002 8 4 2 0 7 0 0 13
2003 5 0 4 0 4 0 0 8
2004 9 0 2 0 5 0 0 7
2005 23 1 8 1 19 1 0 30
2006 35 2 16 2 31 1 2 54
2007 27 0 5 0 19 0 0 24
2008 16 0 5 0 11 1 0 17
Total 134 8 44 3 101 4 2 162
A few case series from Japan describe the rapid develop-
ment of HTLV–1 associated disease in recipients that were
seropositive prior to transplant (17,18); others describe no
cases of HAM/TSP or ATL in seropositive recipients with
extended follow-up (19,20).
Retrospective reviews of the OPTN database have as-
sessed the outcome of elective transplantation of HTLV-
1/2 seropositive organs (7,21) (Table 2). To update these
results, the OPTN database was queried for this group and
identified 162 recipients of 134 donors testing positive for
HTLV-1/2 from 1999 to 2008 (Table 3); 10 developed post-
transplant malignancies but these were skin cancers (ex-
cept for one case of recurrent liver cancer) and no cases of
ATL or post-transplant lymphoproliferative disease were re-
ported. Thirty-three donors were used from 1999 to 2004;
and 101 donors from 2005 to 2008. These studies are
limited as the database does not report if confirmatory
testing was done, so the proportion of organs from con-
firmed HTLV-1-infected donors is not known for these pa-
tients. This would likely underestimate the risk associated
with donor-derived transmission from a true positive HTLV-
1 donor. Further, the results of testing recipients to deter-
mine if HTLV-1/2 transmission occurred are not available
and neurological sequelae is not recorded in the database.
Prevalence of HTLV-1/2 in Organ Donors
While HTLV-1/2 donor antibody testing is required and per-
formed by all OPOs on all prospective donors, only data
on donors whose organs are procured are collected in
the OPTN database. Some European countries have sur-
veyed all potential organ donors; in France 0.047–0.067%
were found to be HTLV-1/2-positive (22). A similar survey
was conducted in Spain; over one-thousand potential or-
gan donors were tested and none was positive for HTLV-1
and one was positive for HTLV-2 (23).
Based on higher rates of immigration from high prevalence
countries, HTLV-1/2 rates would be expected to be higher in
the United States than in Europe. In one study of 1,408 po-
tential donors, 1.6% were positive on repeated EIA testing
with only one patient (0.07%) confirmed positive for HTLV-
1 (6). Similar low rates of HTLV-1 infection among screen
positive donors in Wisconsin was reported (7).
In order to better determine the prevalence of HTLV-1/2
among potential organ donors, we surveyed the results
of several OPOs (those participating in the Ad Hoc HTLV
Donor Screening Advisory Group) regarding their rates
of positive HTLV-1/2 (Table 4). Overall 1.04% of donors
Table 4: HTLV-1/2 seroprevalance among potential organ donors
OPO/Lab
UNOS Donors SCRN SCRN % SCRN CONF CONF CONF CONF CONF CONF % CONF % CONF
REGION Time period screened (−) (+) (+) DONE (+) (−) IND HTLV-1 HTLV-2 HTLV-1/2 HTLV-1 (+)
3 2002–2009 1658 1644 11 0.66% ND ND ND ND ND ND ND ND
3 7/1/92–3/19/09 4169 4150 19 0.46% 18 5 10 3 ND ND 0.12% ND
11 1995–2008 130 129 1 0.77% ND ND ND ND ND ND ND ND
5 2006–2008 3490 3459 31 0.89% 30 22 1 7 1 20 0.63% 0.03%∗
9 1/1/04–3/24/09 349 346 3 0.86% ND ND ND ND ND ND ND ND
10 1/1/06–12/31/08 1273 1267 17 1.32% ND ND ND ND ND ND ND ND
7 05/01/99– 3/01/09 3363 3295 68 2.02% 60 29 19 12 ND ND 0.86% ND
TOTAL 14 432 150 1.04% 108 56 30 22 1 20 0.51% 0.03%
IND = Indeterminate.
Screening done using Abbott HTLV I/II EIA or Abbott PRISM HTLV I/II EIA.
∗Confirmation done using the Genelabs HTLV 2.4 Western blot.
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screened positive for HTLV-1/2; in the three labs in which a
confirmatory assay was performed 0.5% of donors were
confirmed positive for HTLV-1/2 (in these labs, most but
not all positives were confirmed). Only one lab attempted
to distinguish HTLV-1 from HTLV-2 (using Genelabs HTLV
2.4 Western blot), and documented a HTLV-1 positive rate
of 0.03%. While the overall rate of HTLV-1 infection in the
donor population is likely very low, it should be noted that
local areas of higher prevalence, likely based on immigra-
tion patterns from high incidence countries, have been de-
scribed (24,25).
Similar findings have been documented in studies of the
Abbott HTLV-I/II EIA assay among volunteer blood donors
and patients with other medical conditions. Among 15,215
volunteer blood donors, 51 (0.35%) were repeatedly reac-
tive for HTLV-1/2; only 10 (0.07%) of these were positive
on confirmatory testing and 4 (0.03%) had HTLV-1 (12).
In patients with medical conditions unrelated to HTLV-1/2,
higher rates of positive screens are obtained 26/639 (4%);
only 3 (0.47%) were confirmed to be HTLV-1 (12). Thus, in
both our limited data in potential organ donors, volunteer
blood donors and patients with other medical conditions,
most screen positive patients do not have HTLV-1 infection.
Loss of Organs Associated with Current
HTLV-1/2 Screening Strategy
Previous papers have commented on the loss of usable
organs resulting from the high false positive rate with cur-
rently available screening tests (7,21). There are approx-
imately 8000 potential deceased donors reported to the
OPTN database each year for which at least one organ
is procured. Using this information along with the stud-
ies and data presented here, it is estimated that there are
83 potential donors that screen positive for HTLV-1/2; of
these only 2–22 (that is between 3% and 27% based on
the one lab differentiating between HTLV-1 and HTLV-2) are
likely actually infected with HTLV-1; and only 16 screened
positive donors were used during 2008. As a result, be-
tween 45 and 65 donors are not used annually although
they are uninfected with HTLV-1. Further, during 2008 the
average number of organs transplanted per HTLV-1/2- neg-
ative donor was 3; for HTLV-1/2 screen positive donors it
was only 1.1. If one estimates three organs per donor from
the 45–65 donors (135–195 organs) plus the extra two or-
gans from the 16 that were used (32 organs), there is a loss
of 167–227 organs annually using existing technology.
Alternatives to Current Testing Strategy
After December 31, 2009, the Abbott HTLV-I/II EIA used
in most OPOs will no longer be available. Alternative solu-
tions to the current OPTN/UNOS requirement for screen-
ing include the Abbott PRISM HTLV-I/HTLV-II assay, an as-
say using RUO reagents, or forgoing pretransplant screen-
ing for HTLV-1/2.






FDA licensed No Yes
Turn around time 90 minutes 60 minutes
Cost of $12,000 $850,000
instrumentation
Cost of test kit $380 $14,637
Yearly cost of assay $47,500 $912,000
Estimated cost of $65 $1500+
test per donor
∗This assay is not FDA licensed and available for research use only
in the United States.
Abbott PRISM HTLV-I/HTLV-II assay
The Abbott PRISM HTLV-I/ II assay is FDA licensed for HTLV-
1/2 screening and will continue to be supported by Abbott.
This testing system, however, is designed to test large
numbers of samples (up to 160 samples an hour) in a high
throughput setting, and both technical and cost barriers will
impact the availability and usefulness of this assay when
used for single donor testing. OPO lab directors expressed
a number of concerns. The system requires investing in ex-
pensive equipment and reagents that may be wasted when
used as OPOs currently test donors. A significant invest-
ment is also necessary to train laboratory technicians to
ensure proficiency and quality assurance. One large donor
testing laboratory analyzed the costs associated with the
Abbott PRISM HTLV-I/II assay compared to the MP Diag-
nostics HTLV-I/II ELISA 4.0, an RUO assay (Table 5). The
cost per assay is estimated to be >20-fold higher with
the PRISM system (26). Further, many OPOs outsource in
labs in which in they have no control and in such situations,
availability of Abbott PRISM HTLV I/II testing on a stat, after-
hours basis is unlikely. OPO directors were concerned that
mandating the use of the Abbott PRISM HTLV I/II system
could result in delaying organ offers and recovery up to
36 h as samples are sent to large labs to be batched with
nondonor samples.
RUO tests
The group was aware of three manufacturers that pro-
duce RUO serological reagents for HTLV-1/2 testing that
are inexpensive, rapid and have protocols amendable to
being done in OPO laboratories. Currently, a number of
testing laboratories are evaluating these tests side by
side with the FDA-licensed screening assays. In some
of these evaluations, RUO assays that use recombinant
antigens rather than the viral lysate used in the FDA li-
censed assays appear to have lower false positive rates
(27). RUO assays lack a national standard (i.e. FDA licen-
sure) making them less appropriate as part of a national
testing strategy. Even if adequately performing and eval-
uated RUO tests were available, under FDA regulation
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(these assays would be classified as Class III, subject to
either licensing or approval requirements), manufacturers
of RUO tests cannot knowingly provide these tests to labs
if the results will be reported and used for clinical purposes.
Additionally, RUO assays are subject to market forces and
can be discontinued by the manufacturer without notice.
Because of these regulatory requirements and the uncer-
tain performance characteristics of the assays, RUO tests
will not likely be a viable option.
Elimination of the requirement for pretransplant
HTLV-1/2 donor screening
Given the very low prevalence of HTLV-1 in the donor popu-
lation, wastage of organs with the currently available sero-
logical assays, and favorable short-term follow up of re-
cipients of HTLV-1/2 screen positive organs in the United
States, the Committee opined that elimination of pretrans-
plant HTLV-1/2 screening was a reasonable option.
Some members of the group were concerned that the level
of data on outcomes of HTLV-1 positive organs was limited
and that additional information should be collected to in-
form future policy. As one potential option before outright
discontinuing HTLV-1/2 testing, a period of retrospective
testing to obtain more robust prospective data (as opposed
to the retrospective data collected for this paper) on the
true incidence and clinical sequelae of HTLV-1 in donors
and recipients should be considered. After a fixed period
of time, this retrospective testing and its outcomes should
be reviewed to determine if this strategy should be contin-
ued. The Committee recommends that, if this strategy is
implemented, samples can be batched and sent for test-
ing using a FDA-licensed assay, such as the Abbott PRISM
HTLV-I/II, which is currently available through blood centers
and reference labs throughout the country. If this policy is
to be implemented, public comment should be obtained.
There are significant logistic hurdles that would need to
be addressed with retrospective testing: (1) collecting and
storing the appropriate samples to do both the primary
and confirmatory testing for all donors, (2) developing a
consensus on how to inform recipients and how best to
test and monitor recipients post-transplant, and (3) devel-
oping an infrastructure to efficiently collect data on all of
these issues to inform future policy.
Since all existing screening tests do not distinguish be-
tween HTLV-1 and HTLV-2 and have a high false-positive
rate in a low seroprevalence population, it will be essen-
tial to perform confirmatory testing on all screen positive
retrospectively tested samples. The two most commonly
used confirmatory tests are the Genelabs HTLV 2.4 (West-
ern blot) and the Innogenetics HTLV-I/II Line Immunoas-
say. Both tests can be used for confirmation of a positive
screening assay and, in some cases, virus typing (HTLV-
1 vs. HTLV-2). Neither test is FDA-licensed, and cannot
be used for direct clinical purposes. These tests could,
however, be used as part of a protocol to determine the
prevalence of HTLV-1 and HTLV-2 in the donor population.
Likewise, molecular diagnostic tools, such as NAT, could
be used to determine the presence of HTLV-I in the cells
of screen-positive donors, confirming the infection. While
no FDA-licensed test is available, if patients are to be in-
formed post-transplant of positive donor results and confir-
matory testing is not required, the result will be unneces-
sary follow-up and anxiety for patients who have not been
exposed to HTLV-1. Other challenges with retrospective
testing include the stress and potential legal ramifications
associated with disclosing the retrospective results to the
recipients and a lack of data to determine what type of
follow-up is appropriate for these individuals. As a result,
even if viral replication is recognized, it is unclear what
could be done and if an intervention is even warranted as
there is no proven therapy for HTLV-1.
Future Directions
There are a wide range of infectious agents that cause
clinically significant disease when transmitted from donors
to recipients, including HTLV-1. Unfortunately, decisions on
which agents to screen for and development of optimal as-
says have not been made using robust data nor have they
been supported by appropriate research funding. Based
on the current data, the current HTLV-1/2 testing platforms
lead to far greater loss of organs than disease prevention.
As such, interim discontinuation of the requirement for
HTLV-1 testing is appropriate when considering a societal
perspective. Optimally, research needs to be conducted to
understand the true incidence of HTLV-1 in the U.S. donor
population and the natural history of transmitted HTLV-1
infection in the recipient population. Research and devel-
opment of novel screening tests that detects only HTLV-1
are desperately needed; these assays would need to be
developed with organ transplantation in mind such that
they could be applied on a stat basis, and result in the
fewest possible false positive results. Companies should
be encouraged to seek FDA-licensure for these assays.
Given the limited market for these assays, stimulus for
companies to invest in these assays is also needed.
References
1. Blattner WA, Saxinger C, Riedel D et al. A study of HTLV-I and its
associated risk factors in Trinidad and Tobago. J Acquir Immune
Defic Syndr 1990; 3: 1102–1108.
2. Glynn SA, Kleinman SH, Schreiber GB et al. Trends in incidence
and prevalence of major transfusion-transmissible viral infections
in U.S. blood donors, 1991 to 1996. Retrovirus Epidemiology Donor
Study (REDS). JAMA 2000; 284: 229–235.
3. Manns A, Wilks RJ, Murphy EL et al. A prospective study of trans-
mission by transfusion of HTLV-I and risk factors associated with
seroconversion. Int J Cancer 1992; 51: 886–891.
4. Martin-Davila P, Fortun J, Lopez-Velez R et al. Transmission of
tropical and geographically restricted infections during solid-organ
transplantation. Clin Microbiol Rev 2008; 21: 60–96.
212 American Journal of Transplantation 2010; 10: 207–213
HTLV-1/2 Screening of Organ Donors
5. Murphy E, Roucoux D. The epidemiology and disease outcomes
of human T-lymphotropic virus type II. AIDS Rev 2004; 6: 144–154.
6. Nowicki MJ, Matsuoka L, Brucal D et al. High seroprevalence of
anti-HTLV-I/II antibodies among solid organ donors necessitates
confirmatory testing. Transplantation 2006; 82: 1210–1213.
7. Shames BD, D’Alessandro AM, Sollinger HW. Human T-cell lym-
photrophic virus infection in organ donors: A need to reassess
policy? Am J Transplant 2002; 2: 658–663.
8. U.S. Department of Health and Human Services. Organ Procure-
ment and Transplantation Network. Available from: http://optn.
transplant.hrsa.gov/policiesAndBylaws/policies.asp. Accessed
April 23, 2009.
9. US Food and Drug Administrations. Center for Biologics Eval-
uation and Research. [cited 2009 April 24]; Available from:
http://www.fda.gov/cber/tissue/prod.htm#approved
10. Ison MG, Pruett T, Teperman L. Current practices and future chal-
lenges: A survey reported by the OPTN/UNOS Ad Hoc Disease
Transmission Advisory Committee. In: American Transplantation
Congress: 385 Abstract. Boston, 2009.
11. Package Insert: Abbott PRISM HTLV-II/HTLV-II.
12. Package Insert: Abbott HTLV-I/HTLV-II EIA.
13. Package Insert: BioMerieux Vironostika HTLV-I/II Microelisa Sys-
tem.
14. Nakatsuji Y, Sugai F, Watanabe S et al. HTLV-I-associated myelopa-
thy manifested after renal transplantation. J Neurol Sci 2000; 177:
154–156.
15. Remesar MC, del Pozo AE, Pittis MG, Mangano AM, Sen L,
Briones L. Transmission of HTLV-I by kidney transplant. Transfu-
sion 2000; 40: 1421–1422.
16. Toro C, Rodés B, Poveda E, Soriano V. Rapid development of sub-
acute myelopathy in three organ transplant recipients after trans-
mission of human T-cell lymphotropic virus type I from a single
donor. Transplantation 2003; 75: 102–104.
17. Hoshida Y, Li T, Dong Z et al. Lymphoproliferative disorders in
renal transplant patients in Japan. Int J Cancer 2001; 91: 869–875.
18. Kawano N, Shimoda K, Ishikawa F et al. Adult T-cell leukemia de-
velopment from a human T-cell leukemia virus type I carrier after
a living-donor liver transplantation. Transplantation 2006; 82: 840–
843.
19. Nakamura N, Arakaki Y, Sunagawa H et al. Influence of immuno-
suppression in HTLV-1-positive renal transplant recipients. Transpl
Proc 1998; 30: 1324–1326.
20. Tanabe K, Kitani R, Takahashi K et al. Long-term results in human
T-cell leukemia virus type 1-positive renal transplant recipients.
Transpl Proc 1998; 30: 3168–3170.
21. Marvin MR, Brock GN, Kwarteng K et al. Increasing utilization of
human T-cell lymphotropic virus (+) donors in liver transplantation:
Is it safe? Transplantation 2009; 87: 1180–1190.
22. Claquin J, Romano P, Noury D et al. Human T lymphotropic virus
1–2 positive antibodies in potential organ donors in France. Transpl
Proc 1996; 28: 189–190.
23. Toro C, Benito R, Aguilera A et al. Infection with human T lym-
photropic virus type I in organ transplant donors and recipients in
Spain. J Med Virol 2005; 76: 268–270.
24. Harrington WJ Jr., Ucar A, Gill P et al. Clinical spectrum of HTLV-I in
south Florida. J Acquir Immune Defic Syndr Hum Retrovirol 1995;
8: 466–473.
25. Levine PH, Dosik H, Joseph EM et al. A study of adult T-cell
leukemia/lymphoma incidence in central Brooklyn. Int J Cancer
1999; 80: 662–666.
26. Personal communication, National Institute of Transplantation,
Inc., 2009.
27. Personal communication, Carol Pancoska, LABS-Inc., 2009.
28. Nakamura N, Tamaru S, Ohshima K, Tanaka M, Arakaki Y, Miyauchi
T. Prognosis of HTLV-I-positive renal transplant recipients. Transpl
Proc 2005; 37: 1779–1782.
American Journal of Transplantation 2010; 10: 207–213 213
